Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Department for Drug Design and Optimization (DDOP), Campus C2.3, 66123 Saarbrücken, Germany.
Saarland University, Department of Pharmaceutical Biology, Campus C2.2, 66123 Saarbrücken, Germany.
Org Biomol Chem. 2015 Nov 21;13(43):10620-30. doi: 10.1039/c5ob01006c.
This paper focuses on an interesting constitutional isomerism called azido-tetrazole equilibrium which is observed in azido-substituted N-heterocycles. We present a systematic investigation of substituent effects on the isomer ratio within a 2-substituted 4-azidopyrimidine model scaffold. NMR- and IR-spectroscopy as well as X-ray crystallography were employed for thorough analysis and characterization of synthesized derivatives. On the basis of this data, we demonstrate the possibility to steer this valence tautomerism towards the isomer of choice by means of substituent variation. We show that the tetrazole form can act as an efficient disguise for the corresponding azido group masking its well known reactivity in azide-alkyne cycloadditions (ACCs). In copper(I)-catalyzed AAC reactions, substituent-stabilized tetrazoles displayed a highly decreased or even abolished reactivity whereas azides and compounds in the equilibrium were directly converted. By use of an acid sensitive derivative, we provide, to our knowledge, the first experimental basis for a possible exploitation of this dynamic isomerism as a pH-dependent azide-protecting motif for selective SPAAC conjugations in aqueous media. Finally, we demonstrate the applicability and efficiency of stabilized tetrazolo[1,5-c]pyrimidines for Fragment-Based Drug Design (FBDD) in the field of quorum sensing inhibitors.
本文聚焦于一种有趣的称为叠氮四唑平衡的结构异构现象,这种现象存在于取代叠氮基的杂环 N- 化合物中。我们对 2-取代 4-叠氮嘧啶模型骨架中异构体比例的取代基效应进行了系统的研究。NMR 和 IR 光谱以及 X 射线晶体学被用于深入分析和合成衍生物的表征。基于这些数据,我们证明了通过取代基变化来引导这种价态互变异构体向所需异构体的可能性。我们表明,四唑形式可以作为相应叠氮基团的有效伪装,掩盖其在叠氮-炔烃环加成(AAC)反应中的已知反应性。在铜(I)催化的 AAC 反应中,取代基稳定的四唑显示出高度降低甚至消除的反应性,而叠氮化物和平衡化合物则直接转化。通过使用对酸敏感的衍生物,我们提供了,据我们所知,这种动态异构现象作为 pH 依赖性叠氮保护基用于在水相介质中进行选择性 SPAAC 偶联的第一个实验依据。最后,我们展示了稳定的四唑并[1,5-c]嘧啶在群体感应抑制剂领域的基于片段的药物设计(FBDD)中的适用性和效率。